World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
67
Citations
20818
World Ranking
2649
National Ranking
1266

Willem W. Overwijk publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Willem W. Overwijk sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 161 publications — 20th percentile

20% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Willem W. Overwijk D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Willem W. Overwijk sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 67 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Willem W. Overwijk is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research is primarily situated within the fields of Medicine and Immunology and Microbiology, with significant contributions across several subfields including Immunology, Oncology, Neurology, Molecular Biology, and Genetics.

Their work focuses on multiple key topics such as CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Immune Cell Function and Interaction, Neuroblastoma Research and Treatments, Immune cells in cancer, and Microtubule and mitosis dynamics.

Willem W. Overwijk has published extensively, with notable recent papers including:

  • Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy, 2020, Nature Communications
  • Engineering IL-2 to Give New Life to T Cell Immunotherapy, 2020, Annual Review of Medicine
  • Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma, 2021, Cancer Discovery
  • LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade, 2022, Journal of Clinical Investigation
  • Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity, 2020, Cancer Immunology Immunotherapy

The frequent co-authors collaborating with Overwijk include Manisha Singh, Cara Haymaker, Adi Diab, Jason Roszik, and Patrick Hwu.

Publications by Overwijk have appeared regularly in venues such as The Journal of Immunology, Blood Advances, Frontiers in Immunology, Transplantation and Cellular Therapy, and Cancer Research.

Best Publications

  • Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy

    Weiyi Peng;Jie Qing Chen;Chengwen Liu;Shruti Malu

  • Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells

    Willem W. Overwijk;Marc R. Theoret;Steven E. Finkelstein;Deborah R. Surman

  • BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma

    Dennie Tompers Frederick;Adriano Piris;Alexandria P. Cogdill;Zachary A. Cooper

  • Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

    Pei Ling Chen;Whijae Roh;Alexandre Reuben;Zachary A. Cooper

  • T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity

    Natalia Martin-Orozco;Pawel Muranski;Yeonseok Chung;Xuexian O. Yang

  • CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4 T helper cells and hindered by naturally occurring T regulatory cells.

    Paul A. Antony;Ciriaco A. Piccirillo;Akgül Akpinarli;Steven E. Finkelstein

  • GP100/PMEL 17 IS A MURINE TUMOR REJECTION ANTIGEN : INDUCTION OF SELF -REACTIVE, TUMORICIDAL T CELLS USING HIGH-AFFINITY, ALTERED PEPTIDE LIGAND

    Willem W. Overwijk;Allan Tsung;Kari R. Irvine;Maria R. Parkhurst

  • B16 as a mouse model for human melanoma.

    Willem W. Overwijk;Nicholas P. Restifo

  • Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T lymphocytes

    Willem W. Overwijk;David S. Lee;Deborah R. Surman;Kari R. Irvine

  • PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines

    Weiyi Peng;Chengwen Liu;Chunyu Xu;Yanyan Lou

  • Persistent antigen at vaccination sites induces tumor-specific CD8 + T cell sequestration, dysfunction and deletion

    Yared Hailemichael;Zhimin Dai;Nina Jaffarzad;Yang Ye

  • Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine Comparison of Prophylaxis and Therapy

    A. Van Elsas;R. P M Sutmuller;A. A. Hurwitz;J. Ziskin

  • Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.

    Vincenzo Bronte;Michael Wang;Willem W. Overwijk;Deborah R. Surman

  • BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.

    Chengwen Liu;Weiyi Peng;Chunyu Xu;Yanyan Lou

  • Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy

    Tiffany R. Hodges;Martina Ott;Joanne Xiu;Zoran Gatalica

  • Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice

    Chengwen Liu;Yanyan Lou;Gregory Lizée;Hong Qin

  • Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function

    Young Hee Lee;Natalia Martin-Orozco;Natalia Martin-Orozco;Peilin Zheng;Jing Li

  • The immune system in cancer metastasis: friend or foe?

    Louise M.E. Janssen;Emma E. Ramsay;Craig D. Logsdon;Willem W. Overwijk

  • Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy.

    Xiaohong Wang;Jonathan E. Schoenhals;Ailin Li;David R. Valdecanas

  • Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

    Hong Qin;Beatrisa Lerman;Ippei Sakamaki;Guowei Wei

  • Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer

    Brian A. Rabinovich;Yang Ye;Tamara Etto;Jie Qing Chen

Frequent Co-Authors

Patrick Hwu
Patrick Hwu The University of Texas MD Anderson Cancer Center
Nicholas P. Restifo
Nicholas P. Restifo National Institutes of Health
Laszlo Radvanyi
Laszlo Radvanyi Ontario Institute for Cancer Research
Adi Diab
Adi Diab The University of Texas MD Anderson Cancer Center
Steven A. Rosenberg
Steven A. Rosenberg National Institutes of Health
Jennifer A. Wargo
Jennifer A. Wargo The University of Texas MD Anderson Cancer Center
Chantale Bernatchez
Chantale Bernatchez The University of Texas MD Anderson Cancer Center
Michael A. Davies
Michael A. Davies The University of Texas MD Anderson Cancer Center
Padmanee Sharma
Padmanee Sharma The University of Texas MD Anderson Cancer Center
Cara Haymaker
Cara Haymaker The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can open new career avenues. Nursing fields, in particular, offer several pathways with flexible online options. Accelerated nurse practitioner programs provide a fast-track route for professionals seeking advanced practice roles without lengthy traditional study periods. These programs are tailored to equip students with clinical expertise efficiently.

Transitioning within nursing specialties is also common, such as moving from Family Nurse Practitioner (FNP) to Acute Care Nurse Practitioner roles. Understanding the requirements for acute care np certification is essential for those wanting to serve acute care settings effectively.

For individuals without a nursing background, online absn programs for non nurses offer an accessible entry point into nursing careers. These programs are designed to build foundational skills and knowledge quickly for new students.

Salary transparency also plays a critical role in career planning. Resources like the dnp salary transparency guide help prospective students and professionals evaluate where their education and skills might be best rewarded across different states.

Best Scientists Citing Willem W. Overwijk

Trending Scientists

Recently Published Articles